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Since the implementation of several legislations to improve pediatric drug research, more
pediatric clinical trials are being performed. In order to optimize these pediatric trials,
adequate preclinical data are necessary, which are usually obtained by juvenile animal
models. The growing piglet has been increasingly suggested as a potential animal model
due to a high degree of anatomical and physiological similarities with humans. However,
physiological data in pigs on the ontogeny of major organs involved in absorption,
distribution, metabolism, and excretion of drugs are largely lacking. The aim of this study
was to unravel the ontogeny of porcine hepatic drug metabolizing cytochrome P450
enzyme (CYP450) activities as well as protein abundances. Liver microsomes from 16
conventional pigs (8 males and 8 females) per age group: 2 days, 4 weeks, 8 weeks,
and 6–7 months were prepared. Activity measurements were performed with substrates
of major human CYP450 enzymes: midazolam (CYP3A), tolbutamide (CYP2C), and
chlorzoxazone (CYP2E). Next, the hepatic scaling factor, microsomal protein per gram
liver (MPPGL), was determined to correct for enzyme losses during the fractionation
process. Finally, protein abundance was determined using proteomics and correlated
with enzyme activity. No significant sex differences within each age category were
observed in enzyme activity or MPPGL. The biotransformation rate of all three substrates
increased with age, comparable with human maturation of CYP450 enzymes. The
MPPGL decreased from birth till 8 weeks of age followed by an increase till 6–7 months
of age. Significant sex differences in protein abundance were observed for CYP1A2,
CYP2A19, CYP3A22, CYP4V2, CYP2C36, CYP2E_1, and CYP2E_2. Midazolam and
tolbutamide are considered good substrates to evaluate porcine CYP3A/2C enzymes,
respectively. However, chlorzoxazone is not advised to evaluate porcine CYP2E enzyme
Frontiers in Pharmacology | www.frontiersin.org 1 May 2018 | Volume 9 | Article 470
fphar-09-00470 May 9, 2018 Time: 15:46 # 2
Millecam et al. Ontogeny of Porcine CYP450 Enzymes
activity. The increase in biotransformation rate with age can be attributed to an increase
in absolute amount of CYP450 proteins. Finally, developmental changes were observed
regarding the involvement of specific CYP450 enzymes in the biotransformation of the
different substrates.
Keywords: cytochrome P450, ontogeny, MPPGL, pig, proteomics, enzyme activity, intrinsic clearance
INTRODUCTION
It has been about 20 years since the first pediatric legislations
were initiated by the EMA and the FDA to stimulate pediatric
drug research. Over the years this has led to an increased
number of pediatric clinical trials, new medicines and pediatric
indications both in the European Union and the United States
(Califf, 2016; EMA, 2016). In order to support the safety of these
pediatric trials, it is important to improve and optimize pediatric
preclinical studies. Pediatric juvenile animal studies can provide
essential information regarding the PK, PD and safety of a drug.
According to the ICH guideline M3(R2), these studies should
only be considered when previous animal data and human safety
data are insufficient to support pediatric studies. If a juvenile
study is warranted, only one relevant species, preferably rodent, is
generally considered adequate. This is in contrast with preclinical
studies in adults where both rodent and non-rodent species
are mandatory (Food and Drug Administration, HHS, 2010).
When selecting the appropriate animal species, it is important to
take the maturation and growth of the different organ systems
into account. From a historical point of view the rat is still
the species of first choice when performing pediatric preclinical
studies (Andrew et al., 2013). However, more recent reports
suggest the pig (Sus scrofa domestica) as a valuable alternative
animal model to the rat (Bode et al., 2010; Swindle et al., 2012;
Helke and Swindle, 2013). Gasthuys et al. (2016) reported a
high level of anatomical and physiological similarities between
conventional pigs and humans during the developmental stages
of life, rendering the piglet a suitable juvenile animal model.
Nevertheless still a lot of knowledge gaps remain, such as the
maturation of ADME processes both in growing children and
piglets.
CYP450 enzymes are the most important phase I drug
metabolizing enzymes, located on the smooth endoplasmic
reticulum and highly expressed in liver compared to other tissues
in pigs (Antonovic and Martinez, 2011; Nielsen et al., 2017).
Abbreviations: ACN, acetonitrile; ADME, absorption, distribution, metabolism,
and excretion; CaCl2, calcium chloride; CID, collision induced dissociation;
CYP450, cytochrome P450; DMSO, dimethyl sulfoxide; DTT, dithiothreitol;
EMA, European Medicines Agency; ESI, electrospray ionization; FDA,
Food and Drug Administration; HD-DDA, high definition-data dependent
analysis; ICH, International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use; IVIVE,
In vitro to in vivo extrapolation; KCl, potassium chloride; KCN, potassium
cyanide; KM, Michaelis-Menten constant; MMTS, methyl methanethiosulfonate;
MPPGL, microsomal protein per gram liver; MS, mass spectrometry;
NADPH, β-nicotinamide adenine dinucleotide phosphate; NCR, NADPH-
cytochrome c reductase; PD, pharmacodynamics; PK, pharmacokinetics; TEABC,
triethylammonium bicarbonate buffer; UHPLC-MS/MS, ultra-high performance
liquid chromatography tandem mass spectrometry; UPLC, ultra-performance
liquid chromatography; Vmax, maximum rate.
They metabolize between 70 and 80% of the human drugs used,
most frequently by hydroxylation (Matalová et al., 2016). The
ontogeny of the human CYP450 enzymes is rather well known.
For example CYP2C9 enzyme activity increases rapidly after
birth reaching adult values around 3 months of age, whereas
CYP1A2 reaches adult values around 10 years of age (Alcorn and
McNamara, 2002; Johnson et al., 2006; Matalová et al., 2016).
In contrast to men, the ontogeny of CYP450 enzymes in pigs
remains largely unknown. Hu (2015) reported in Camborough-
29 pigs an increase in average total CYP450 contents in
liver microsomes and in biotransformation rate with age for
six different substrates (phenacetin, coumarin, tolbutamide,
bufuralol, chlorzoxazone, and midazolam) (Hu, 2015). Postnatal
maturation of CYP450 enzyme activity in liver microsomes of the
Göttingen minipig using four different substrates (phenacetin,
tolbutamide, midazolam, and dextromethorphan) was reported
by Van Peer et al. (2017). In general, CYP3A4, CYP2C9, and
CYP2E1 are estimated to contribute to the metabolism of
over 50% of human drugs currently on the market (Alcorn
and McNamara, 2002). There is evidence that the three probe
substrates, midazolam, tolbutamide, and chlorzoxazone, which
are often used in the pharmaceutical industry for human in vitro
work, are biotransformed to the same metabolites in pigs as
in humans (Yuan et al., 2002; Helke and Swindle, 2013). The
1-hydroxylation of midazolam, 4-hydroxylation of tolbutamide,
and 6-hydroxylation of chlorzoxazone have been used before as
markers for, respectively, CYP3A, CYP2C, and CYP2E in pigs
(Hu, 2015; Van Peer et al., 2017). Although high percentages
of sequence identity of nucleotides and amino acids between
pigs and humans are present, this is not always reflected in
the substrate affinities (Puccinelli et al., 2011). For example,
tolbutamide which is a selective substrate for human CYP2C9
shows some cross-reactivity in pigs, indicating that either the
substrate is not specific or other enzymes are involved in the
biotransformation (Skaanild, 2006).
When using microsomes to examine the biotransformation of
drugs, the final goal is determining the intrinsic clearance and
extrapolation to in vivo (IVIVE). This can be done by using
hepatic scaling factors such as the MPPGL. In men, the MPPGL
increases from birth (26 mg/g) to a maximum of 40 mg/g at
approximately 28 years of age, followed by a gradual decrease
with aging (Barter et al., 2007, 2008). In pigs, this has only been
done in two Suffolk White adult pigs obtaining values of 32.6
and 36.2 mg/g liver (Achour et al., 2011). Finally, the intrinsic
clearance can be calculated with liver weight as a second scaling
factor (Barter et al., 2007).
Another important factor in IVIVE is the CYP450 protein
abundance. Barter et al. (2013) integrated specific abundances
and phenotypes associated with several CYP450s in Caucasian
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and Chinese population models. This led to simulation of
observed population differences in the clearance of several
reference drugs. Regarding the pediatric population, and
especially children younger than 2 years of age, Johnson et al.
(2006) showed that physiologically based models resulted in
better predictions than simple allometric scaling. The CYP450
protein abundances can thus support a better quantitative
understanding of species differences and result in better scaling
of PK and safety data to the clinical setting.
The aim of the current study was to gain more insight in the
ontogeny of porcine CYP450 enzymes. First, the CYP450 enzyme
activity was determined in hepatic microsomes using three probe
substrates (midazolam, tolbutamide, and chlorzoxazone) in four
age categories of growing piglets. Next to activity measurements,
the MPPGL was determined in order to calculate the intrinsic
clearance. Finally, the protein abundance of hepatic CYP450 in
the microsomes was measured and compared with the enzyme
activity.
MATERIALS AND METHODS
Chemicals
The following chemicals were purchased from VWR
(Oud-Heverlee, Belgium), dipotassium hydrogen phosphate,
potassium dihydrogen phosphate, KCL, and glycerol.
Tolbutamide (TB), chlorzoxazone (CZ), chlorpropamide,
formic acid, cytochrome c from equine heart, KCN, TEABC,
DTT, MMTS, CaCl2, DMSO were purchased from Sigma-
Aldrich (St. Louis, MO, United States). Xylazine (Xyl-M R© 2%)
was obtained from VMD (Arendonk, Belgium). Tiletamine-
zolazepam (Zoletil R© 100) was purchased from Virbac (Carros,
France). Sodium pentobarbital 20% R© was obtained from Kela
(Hoogstraten, Belgium). The Coomassie Bradford Protein
Assay Kit was purchased from Thermo Fisher Scientific
(Asse, Belgium). Midazolam (MDZ), 1-hydroxy-midazolam
(1-OH-MDZ), 6-hydroxy-chlorzoxazone (6-OH-CZ), and
4-hydroxy-tolbutamide (4-OH-TB) were all obtained from
Alsachim (Illkirch-Graffenstaden, France). NADPH was
purchased from Gentaur (Kampenhout, Belgium). UPLC-
water and ACN were obtained from Biosolve (Valkenswaard,
Netherlands). Trypsin was purchased from Promega (Madison,
WI, United States). Beta-galactosidase was purchased from Sciex
(Framingham, MA, United States). Hi3 E. coli was purchased
from Waters (Zellik, Belgium). The stock solutions of the probe
substrates, the metabolites and the internal standard were
prepared separately in methanol (MeOH) at a concentration of
1 mg/mL and stored at−80◦C.
Animals and Sample Collection
The current study was approved by the ethical committee of the
Faculties of Veterinary Medicine and Bioscience Engineering of
Ghent University (EC2016/105). Care and use of the animals was
in full compliance with the national (Belgian Royal Decree of 29
May 2013) and European legislation on animal welfare and ethics
(Anonymous, 2010/63/EU). Sixteen pigs (8 barrows and 8 sows,
Hybrid sow × Piétrain boar) aged 2 days, 4 weeks, and 8 weeks
were purchased from Gesuporc BVBA (Vorselaar, Belgium).
Eight intact boars aged 6 months and eight sows aged 7 months
(Large white × Land race, Seghers hybrid) were purchased
from RA-SE Genetics and Convis (Ettelbruck, Luxembourg). The
same strain of Seghers hybrids were used as the mothers of the
younger age categories, thus reducing interindividual variability.
The 2-day, 4-week, and 8-week males were castrated. However,
the mean age for boars to reach puberty was reported to be at
21 weeks of age, while at 26 weeks of age only 8–31% of gilts were
in puberty according to Van den Broeke et al. (2015). Therefore,
no effect of castration (and thus sex hormones) is expected on the
results. The four chosen age categories represent different groups
of growing children. Two-day-, four-week-, eight-week-, and
six-to-seven-month-old pigs correspond with neonates, infants,
children, and adolescents, respectively (Shayne, 2015). The sows
were 1 month older than the boars as females reach puberty
later compared to males (Van den Broeke et al., 2015). All
pigs were weighed (BW, kg) and euthanized at arrival at the
test facility by intramuscular injection of a mixture of xylazine
and tiletamine-zolazepam, followed by intracardial injection of a
sodium pentobarbital overdose. The liver was excised, patted dry
with compresses and weighed (LW, g). A piece of the right liver
lobe (1.22–8.18 g) was snap-frozen in liquid nitrogen and stored
at −80◦C until microsome preparation. CYP450 enzymes were
stable in frozen liver samples for up to 4 months of storage time
(Schelstraete et al., 2018).
Preparation of Microsomes
Microsomes were prepared as described by Goossens et al.
(2013) using the differential ultracentrifugation method (Wilson
et al., 2003). In short, liver samples were thawed on ice
while soaking in homogenization buffer (0.25 M aqueous
phosphate buffer containing 1.15% KCl, pH 7.25). The liver
tissue was weighed, minced with a scissor and homogenized
in 16 mL of homogenization buffer using a Potter-Elvehjem
system (VWR). An aliquot of the homogenate was frozen
(−80◦C) in order to determine the MPPGL (see section
“Microsomal Protein per Gram Liver”). After centrifugation
(Beckman L8-70M Ultracentrifuge, Beckman Coulter Limited,
High Wycombe, United Kingdom) at 10,000 g for 25 min at 4◦C,
the supernatant was centrifuged at 100,000 g for 80 min at 4◦C.
The microsomal pellet was washed by resuspension in 16 mL of
homogenization buffer, followed by centrifuging according to the
latter conditions. The final microsomal pellet was resuspended
in 1.5 mL/g liver tissue resuspension buffer (0.25 M aqueous
phosphate buffer containing 1.15% KCl and 30% glycerol, pH
7.25). The microsomal suspension was snap-frozen in liquid
nitrogen and stored at−80◦C until further analysis.
CYP450 Activity Measurements
Activity measurements were performed as described by Goossens
et al. (2013). Total protein concentration in the microsomes was
determined using the Bradford assay (Bradford, 1976). Three
different probe substrates, namely midazolam, chlorzoxazone,
and tolbutamide, were used to determine the CYP3A, CYP2E,
and CYP2C enzyme activity, respectively. The formation
rate of 1-hydroxy-midazolam, 6-hydroxy-chlorzoxazone, and
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4-hydroxy-tolbutamide was analyzed, respectively. In order to
optimize the ideal incubation conditions, the linearity, KM and
maximum biotransformation rate (Vmax) were determined on a
pool of four 6 months old pigs (results not shown). An apparent
KM of 13.7, 126.2, and 613.2 µM for midazolam, chlorzoxazone,
and tolbutamide, respectively, was determined. The apparent
Vmax was estimated at 281.3, 1210.1, and 153.3 µmol/min/mg
microsomal protein, respectively. The incubation conditions
were as follows. The preheated (37◦C) incubation mixture
consisted of 50 µL of 1.15% KCl in water, 50 µL of 0.05 M
aqueous phosphate buffer (pH 7.4), and 50 µL of substrate
in water mixed with 50 µL NADPH (final concentration
of 1 mM). After 3 min of pre-incubation, the enzymatic
reaction was initiated by addition of 50 µL of microsome
suspension. The microsomes were diluted in a 1.15% KCl
solution, resulting in a final concentration of 0.25 mg/mL in
the incubation mixture for all substrates. Midazolam (10 µM)
was incubated for 10 min, while chlorzoxazone (100 µM)
and tolbutamide (100 µM) were incubated for 20 min. After
the specified incubation time, the enzymatic reactions were
terminated by adding 25 µL of ice cold water/ACN/formic
acid mixture [42/55/3, (v/v/v)], containing the internal standard
chlorpropamide (final concentration of 0.072 µM). Next, the
incubation mixtures were vortexed and transferred on ice.
Subsequently, the samples were centrifuged at 20,000 g for
10 min (4◦C) after which the supernatant was collected and
frozen at −20◦C until analysis. Each microsomal sample was
incubated separately with the three substrates in triplicate. The
metabolites formed during these incubations were quantified
using a validated UHPLC-MS/MS method (De Bock et al.,
2012).
The microsomal activity expressed as pmol/min/mg
microsomal protein was corrected to nmol/min/g liver by
means of the MPPGL (equation 1; section “Microsomal Protein
per Gram Liver”).
Enzyme activity (nmol/min/g liver) = (Microsomal
activity (pmol/min/mg microsomal protein)∗
MPPGL (mg/g liver))/1000 (Eq. 1)
Microsomal Protein Per Gram Liver
The MPPGL of each pig (2-day-old ♂ = 2, ♀ = 8; 4 weeks,
8 weeks, and 6–7 months each time ♂ = 8, ♀ = 8) was
calculated after determination of the microsomal recovery
factor. This recovery factor was estimated by analyzing the
NCR activity in homogenate and microsomes, according to
Guengerich et al. (2009). Homogenate and microsomes were
both diluted to 60 mg/mL (100 mg/mL for the 2-day-old
piglets). 0.5 mM equine heart cytochrome c in 10 mM aqueous
potassium phosphate buffer (pH 7.7) was prepared and frozen
(−20◦C) until use. Nine-hundred microliters of 0.3 M potassium
phosphate buffer (pH 7.7) containing 1 mM KCN, 80 µL of
cytochrome c (0.5 mM) and 10 µL of the diluted homogenate
or microsomes were mixed. After addition and mixing of
10 µL of reduced NADPH solution (10 mM in water), the
absorbance was monitored at 550 nm for 4 min. The rate of
cytochrome c reduction or NCR was calculated according to
equation 2:
1A550/min/0.021 = nmol of cytochrome c reduced per
minutein the cuvette (Eq. 2)
The microsomal recovery factor was then calculated by the
ratio of the NCR in the microsomes and the homogenate.
Finally the MPPGL was calculated by the following equation
(equation 3):
MPPGL (mg/g) = yield of microsomal protein (mg/g)/
microsomal recovery factor (Eq. 3)
CYP450 Protein Abundancy
Measurement: HD-DDA MS Experimental
Set-up
Microsomal proteins (20 µg) of each individual pig were reduced
in 0.5 M TEABC and 1 mM DTT for 1 h at 60◦C, followed by
alkylation using 10 mM MMTS for 10 min at room temperature.
Digestion of proteins into peptides was performed using trypsin
(33:1 protein/enzyme ratio) overnight at 37◦C with CaCl2 and
ACN to a final concentration of 1 mM and 5%, respectively,
as described earlier (Glibert et al., 2014). After evaporation, the
samples were resuspended in 0.1% formic acid. Four hundred
nanograms sample was spiked with 50 fmol beta-galactosidase
and 50 fmol Hi3 E. coli standards before injection.
The peptides were separated using a nanoscale UPLC system
(nanoACQUITY UPLC R©, Waters, Milford, MA, United States)
coupled to a Synapt G2-Si mass spectrometer (Waters). Peptides
were first trapped in 0.1% formic acid on a 180 µm × 20 mm
C18 Trap column. Separation was performed on a HSS C18
1.8 µm, 75 µm × 250 mm analytical column at a flow rate of
300 nL/min and a temperature of 45◦C. Mobile phase A and
B were composed of, respectively, 0.1% formic acid with 4%
DMSO in UPLC-water and 80% ACN containing 0.1% formic
acid. Peptides were separated with a linear gradient for 60 min at
1–40% solvent B and for 1 min 40–85% solvent B. The Q-TOF
Synapt G2-Si instrument was operated in positive mode for
High Definition-DDA, using a nano-ESI source, acquiring full
scan MS and MS/MS spectra (m/z at 50–5,000) in resolution
mode. Survey MS scans were acquired using a fixed scan time
of 200 ms. Tandem mass spectra of up to eight precursor ions
with charge state 2+ to 5+ were generated using CID in the
trapping region with intensity threshold set at 3,000 cps, using
a collision energy ramp from 6/9 V (low mass, start/end) up to
147/183 V (high mass, start/end). MS/MS scan time was set to
100 ms with an accumulated ion count ‘TIC stop parameter’ of
100,000 cps allowing a maximum accumulation time of 250 ms.
Dynamic exclusion of fragmented precursor ions was set to 12 s.
Ion mobility wave velocity was ramped from 2,500 to 400 m/s
for wideband enhancement to obtain a near-100% duty cycle on
singly charged fragment ions. LockSpray of glufibrinopeptide-B
(m/z at 785.8427) was acquired at a scan frequency of 60 s.
Data analysis of the raw files obtained from the Synapt G2-
Si was performed in ProgenesisTM QI (Nonlinear Dynamics)
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version 2.3. Peptides with charge +1 were discarded. For relative
quantification, data was normalized to all proteins. For absolute
quantification, data was normalized to Hi3 E. coli peptides.
Peptide identification was performed with Mascot 2.5, the
following search criteria were set: trypsin as digestion enzyme, up
to two missed cleavages allowed, fixed modification of methylthio
cysteine and variable modifications of methionine oxidation and
deamidation at asparagine and glutamine. Peptide mass tolerance
was set to 15 ppm and fragment mass tolerance to 0.2 Da. Protein
identifications were obtained by searching a compiled database
of reviewed Sus scrofa entries (SwissProt), supplemented with
unreviewed CYP proteins and fragments of interest, the cRAP
database (laboratory proteins and dust/contact proteins1) and
sequences of spiked standard proteins. For relative quantification,
the top three peptides were used and only proteins with at
least one unique peptide were further considered. For absolute
quantification, proteins were quantified using the top three
unique peptides against Hi3 E. coli peptides, and only proteins
with at least one unique peptide were further considered. Protein
data was exported from ProgenesisTM for further statistical
analysis.
Statistical Analysis
Sex and age differences in enzyme activity, MPPGL, and protein
abundances were analyzed by a two-way nested ANOVA on the
log-transformed data. Homogeneity of variances was evaluated
using Levene’s test. Tukey’s honest significant difference test
was performed post hoc. P-values equal to or below 0.05
were considered significant. A non-parametric Spearman rank
correlation test was used to identify relationships between
CYP450 protein abundancy and activity for each age category
separately, and all ages together. CYP450 proteins with a
correlation coefficient equal to or bigger than 0.7 were considered
to be involved in the biotransformation of the substrate
if more than seven correlations were statistically significant
(p < 0.05). All analyses were performed in Rstudio (version
1.0.153, RStudio Inc, Boston, MA, United States). Finally,
stepwise linear regression analysis was performed on the log-
transformed data to evaluate allometric relationships for the
intrinsic clearance (biotransformation rate for the full liver)
and protein abundance of the involved CYP450 proteins as
determined in the correlation analysis. Liver weight, body
weight, and sex were the covariates of interest (SPSS 23, IBM,
United States).
RESULTS
CYP450 Enzyme Activity
The microsomal enzyme activity (pmol/min/mg microsomal
protein) increased with age for the three substrates
(Supplementary Figure S1). No significant sex differences
were found within the different age groups when the activity
was expressed as per mg microsomal protein. This activity was
corrected for enzyme losses during the fractionation process
1http://www.thegpm.org/crap/
according to equation 1. The main effect of gender was significant
(P < 0.05) for chlorzoxazone when the activity was converted
to per g liver. Overall, the biotransformation rate for the three
substrates increased with age, but differently according to the
enzymes involved (Figure 1).
Microsomal Protein Per Gram Liver
The protein content estimated by the Bradford assay was
corrected for protein loss using the microsomal recovery factor.
The MPPGL calculated according to equation 3 is depicted in
Figure 2. The main effect of gender within the age groups was
significant (P < 0.05) and at 8 weeks of age sex differences
were found to be significant. The youngest age category had a
significant higher MPPGL compared to the other age categories.
Significant differences were also observed between the 4-week-
old pigs and the 8-week-old pigs and the 8-week-old pigs and
6- to 7-month-old pigs. No significant differences were observed
between the 4-week-old pigs and the 6- to 7-month-old pigs.
CYP450 Protein Abundancy
In total 255 proteins were retrieved in the liver microsomes.
Twenty CYP450 proteins were identified from which 12 had 3
or more unique peptides (Supplementary Table S1). All unique
peptides were verified in Mascot. Two different CYP2E1 proteins
were found which have a different protein existence. This is
shown as a number after an underscore, namely CYP2E1_1 and
CYP2E1_2. Number 1 means there is experimental evidence at
protein level for the existence of the protein. The criteria include
partial or complete Edman sequencing, clear identification by
MS, X-ray, or NMR structure, good quality protein–protein
interaction or detection of the protein by antibodies. The number
2 means there is evidence of protein existence at transcript level
which means that the existence has not been strictly proven
but that expression data (such as existence of cDNA(s), RT-
PCR or Northern blots) indicate the existence of a transcript.
Verification of these two proteins identified small differences
in sequence, hence, these enzymes were considered as two
different proteins. A relative quantification was performed to
evaluate sex and age differences for every CYP450 enzyme
found (Supplementary Figure S2). Significant sex differences
in abundancy were only found in the 6- to 7-month-old
pigs for CYP1A2, CYP2A19, CYP3A22, CYP2E1_1, CYP2E1_2,
CYP4V2, and CYP2C36. The absolute quantification against
Hi3 E. coli peptides was used to visualize the maturation
of CYP450 enzymes in microsomes (Figure 3). The CYP450
proteins in the 6- to 7-month-old pigs were used as reference
and are represented as a full pie of 100%. This abundancy
was used to calculate the percentage CYP450 protein of the
younger age categories. The individual percentages per age
category can be found in Supplementary Table S2. A graphical
overview of the absolute amount of CYP450 proteins (fmol)
found in microsomes for every age category and per sex can
be found in Supplementary Figure S3. In total 133.2 (±7.91),
435.2 (±30.83), 488.5 (±31.89), 683.3 (±47.67), and 1,186.8
(±108.11) pmol CYP450 proteins per mg microsomal protein
were determined for 2-day-, 4-week-, 8-week-, 6- and 7-month-
old-pigs, respectively.
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FIGURE 1 | The biotransformation rate of midazolam to 1-hydroxy-midazolam (A), tolbutamide to 4-hydroxy-tolbutamide (B) and chlorzoxazone to
6-hydroxy-chlorzoxazone (C), expressed as nmol per min per gram liver of conventional pigs (2-day-old ♂ = 2, ♀ = 8; 4 weeks, 8 weeks, and 6–7 months, each time♂ = 8, ♀ = 8). No significant sex differences within the age groups were observed. Different letters indicate significant differences (P < 0.05) between the different
age groups. The boxplots give the median, 25th and 75th percentiles. The upper and lower whisker extends from the hinge to the largest/smallest value,
respectively, no further than 1.5 times the interquartile range. Data beyond the end of the whiskers are outliers and plotted individually.
Correlation CYP450 Protein Abundance
Versus Enzyme Activity
The results of the Spearman rank test can be found in the
correlation matrices presented in Supplementary Figure S4.
To evaluate which enzyme might be involved in the
biotransformation of the probe substrates over all age categories,
a correlation coefficient of at least 0.7 was assumed when more
than seven CYP450 proteins showed a statistically significant
(P < 0.05) correlation. The results for each age category, and all
ages together can be found in Table 1.
Regression Models
The log-transformed activity and abundancy data showed a linear
relationship which is in support with the principle of allometric
scaling. Both intrinsic clearance and protein abundance showed
a better fit toward liver weight instead of body weight. Details on
the best fits can be found in Table 2. Figure 4 gives an overview
of the defined models with the corresponding observations.
Additionally, the log ratio of the intrinsic clearance to the
corresponding amount of biotransforming CYP450 proteins in
the full liver was calculated. No correlation could be observed in
function of the log liver weight.
DISCUSSION
Despite an increasing amount of data suggesting the piglet as a
suitable animal model for pediatric preclinical studies, a lot of
knowledge gaps still remain. Especially data on the ontogeny of
the different organ systems involved in the ADME processes are
lacking. This information is crucial to make reliable predictions
of the behavior of a drug in growing children, based on juvenile
animal data.
Microsomal Protein Per Gram Liver
One of the strategies to predict in vivo drug clearance in humans,
is to extrapolate based on in vitro data. The initial step in
this process is to convert in vitro microsomal enzyme activity
expressed as units per milligram protein to per gram whole
liver. This conversion is mostly done by a hepatic scaling factor
such as the MPPGL. In humans, different adult values of 33,
40, and 52.9 mg/g liver were reported (Lipscomb et al., 2003;
Wilson et al., 2003; Hakooz et al., 2006). The differences in adult
MPPGL can be due to the liver source, disease state, and/or
experimental methodologies. De Bock et al. (2014) measured an
average value of 18.73 mg/g in four children with a mean age
of 1.17 years suffering from biliary atresia. Barter et al. (2008)
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FIGURE 2 | Boxplot of the microsomal protein per gram liver (MPPGL) with
increasing age of conventional pigs (2-day-old ♂ = 2, ♀ = 8; 4 weeks,
8 weeks, and 6–7 months, each time ♂ = 8, ♀ = 8). The boxplots give the
median, 25th and 75th percentiles. The upper and lower whisker extends
from the hinge to the largest/smallest value, respectively, no further than 1.5
times the interquartile range. Different letters indicate significant differences
(P < 0.05) between the different age groups. The asterisk shows significant
sex differences within the age group.
suggested increasing MPPGL values from birth (26 mg/g) to a
maximum of 40 mg/g at around 28 years of age, followed by a
gradual decrease when aging. However, it should be noted that
the data from Barter et al. (2008) are based on a limited number of
pediatric livers (11 fetal, age not provided; and 5 pediatric, mean
age of 7.8 years). In the current study in pigs, the ontogeny of
the MPPGL showed a different slope compared to the model of
Barter et al. (2008). A decrease from 26.7 mg/g in neonatal piglets
to 15.6, 11.7, and 14.4 mg/g at, respectively, 4 and 8 weeks and
2 6–7 months was demonstrated. Only one other study was
found that determined the porcine MPPGL. Achour et al. (2011)
reported a higher value of 32.6 and 36.2 mg/g liver in two Suffolk
White adult pigs. These higher values compared to the values
reported in the current study can be due to breed differences.
Furthermore, the age was not exactly specified. To the authors
knowledge, no study is available where the MPPGL is determined
in growing piglets. In order to evaluate whether the porcine
MPPGL can be extrapolated to humans, more pediatric data is
mandatory in addition to the data provided by Barter et al. (2008).
CYP450 Enzyme Activity
The biotransformation rate of midazolam in pigs showed a steep
increase during the first weeks of life followed by a gradual
increase till 6–7 months of age. An increase in midazolam
biotransformation rate with age was also observed by Hu (2015)
in Camborough-29 pigs and by Van Peer et al. (2017) in
Göttingen minipigs. In humans, midazolam is used as a selective
probe for CYP3A4/5 enzyme activity. Several human models
based on in vitro midazolam activity data have been proposed
showing the maturation of CYP3A4 with age (Björkman, 2005;
Edginton et al., 2006; Johnson et al., 2006). The human
maturation curves are in line with the results found in the
current study. Edginton et al. (2006) reported an enzyme activity
greater than adult values around the first year or two of life. This
higher activity is also observed in 4-week-old piglets compared to
8-week-old piglets (Figure 1).
The enzyme activity of tolbutamide in pigs, which is a specific
human CYP2C9 substrate, increased gradually to a plateau with
adult values reached at 8 weeks of age. Hu (2015) noticed a
slightly different maturation curve in pigs, where no plateau was
reached at 20 weeks of age. In humans, Johnson et al. (2006)
reported a similar maturation curve as observed in the current
study, where adult values are reached around 6 years of age.
It should be mentioned that maturation curves in humans are
based on a limited number of pediatric individuals and most liver
samples are donated by diseased children, while all experiments
in the current study were performed on healthy piglets.
The maturation curve for chlorzoxazone changed drastically
after scaling with the MPPGL. This is in contrast to midazolam
and tolbutamide, where no differences in maturation were
observed whether the activity was expressed as pmol/min/mg
protein or nmol/min/g liver. When expressed as pmol/min/mg
microsomal protein, the chlorzoxazone activity gradually
increased during the first 8 weeks of life, reaching a plateau
at 6–7 months of age. When expressed as nmol/min/g liver,
the activity remained constant during the first 8 weeks of
life and increased when reaching puberty. This demonstrates
the importance of a hepatic scaling factor taking the enzyme
losses during microsome preparation into account, such as
the MPPGL used here. Moreover, Zhang et al. (2015) found
the CYP450 activity based on liver tissue to be superior to the
CYP450 activity based on microsomal proteins in human. The
maturation curve for human CYP2E1, as predicted by Johnson
et al. (2006), is different than the maturation curve for the
porcine chlorzoxazone biotransformation. This is probably due
to the fact that chlorzoxazone is metabolized by more or other
porcine enzymes than CYP2E1 (Wiercinska and Squires, 2010).
CYP450 Protein Abundancy
In order to identify which CYP450 enzyme is involved in
the biotransformation of a certain substrate, a correlation
analysis between the enzyme abundance in the microsomes
and the activity was performed. It is assumed that the more
enzyme is present, the higher the transformation rate will be. In
literature, protein abundances are mostly determined via mRNA
expression (PCR) or immunoquantification (Anzenbacher
et al., 1998; Skaanild and Friis, 2008; Rasmussen et al.,
2011). Disadvantages of these techniques are that due to
posttranslational modifications, the amount of protein is
not strictly regulated by the expression of mRNA. Also, the
human or rat antibodies used for immunoquantification are
prone to cross-selectivity. Furthermore, a selection of CYP450
enzymes of interest has to be made prior to the experiments.
The latter is in contrast with the proteomics approach used in
the current study, where the enzyme activity can be correlated
with all CYP450 proteins found in the microsomes. Overall
for midazolam, it was shown that CYP3A46, CYP3A22, and
CYP3A are involved in the biotransformation to 1-hydroxy-
midazolam when all pigs of all age categories were analyzed
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FIGURE 3 | Ontogeny of CYP450 enzymes in growing conventional piglets (2-day-old, 4 weeks, 8 weeks and 6–7 months, each time ♂ = 8, ♀ = 8). Six to seven
months old pigs are used as reference and CYP450 abundancy is represented as a full pie of 100%. Since this is the only age category where significant sex
differences were found, separate charts for male (D) and female (E) are shown. For the 2-day- (A), 4-week- (B) and 8-week-old (C) piglets, the average of both
sexes is presented.
together. These CYP450 show a high percentage of identity
with their equivalent human CYP450 enzymes, CYP3A4/5/7/43
(Supplementary Table S1). Midazolam could thus be considered
as a selective porcine substrate to evaluate the CYP3A enzyme
activity. However, when looking at the individual age categories
it seems that only at 6–7 months of age CYP3A22 showed a high
correlation with midazolam biotransformation. In the younger
age categories other CYP450 proteins seem to be involved
in the biotransformation. This might be an indication that
during development other CYP450 enzymes take over when the
CYP450 of interest is not yet abundant enough. For example, van
Waterschoot et al. (2008) observed in CYP3A knockout mice
midazolam biotransformation by upregulated CYP2C enzymes.
Regarding tolbutamide, CYP2C34, CYP2C35, CYP2C36, and
CYP2C49 are involved in its biotransformation when evaluating
all age categories together. These porcine CYP450 enzymes have
73.1–80.6% of identity with human CYP2C8/9/18/19, suggesting
tolbutamide to be a good substrate to evaluate porcine CYP2C
activity. The CYP2C family is involved in the tolbutamide
biotransformation from 2-day-old piglets onwards, but at
6–7 months of age it appeared that CYP2B22 and CYP51A1 also
contributed to the biotransformation. It was already reported
that chlorzoxazone might be a poor substrate to evaluate
CYP2E activity in pigs (Skaanild, 2006; Wiercinska and Squires,
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TABLE 1 | CYP450 proteins showing a statistically significant (P < 0.05) Spearman correlation coefficient with the different substrates.
2-Day-old (n = 16) 4-Week-old
(n = 16)
8-Week-old (n = 16) 6- to 7-months-old
(n = 16)
All pigs (n = 64)
Midazolam CYP4A
CYP4A24
/ CYP2C34
CYP2C49
CYP1A2
CYP2A19
CYP3A
CYP3A22
CYP2E1
(PE = 1 and PE = 2)
CYP3A46,
CYP3A,
CYP3A22
Tolbutamide CYP2C33v4
CYP2C49
CYP2D6
CYP2C49
CYP2C34
CYP2C34
CY· ·2C35
CYP2C36
CYP2C49
CYP4V2
CYP2B22
CYP2C34
CYP2C35
CYP2C36
CYP3A
CYP51A1
CYP2C35,
CYP2C49,
CYP2C36,
CYP2C34
Chlorzoxazone CYP2C34 / CYP2A19 CYP1A2
CYP2A19
CYP3A
CYP3A22
CYP2E1
(PE = 1 and PE = 2)
CYP4V2
CYP3A46,
CYP3A,
CYP2C33v4
Each age category consists of 8 males and 8 females. / No statistically significant correlation coefficient was found. PE, protein existence, these are two different CYP2E1
proteins.
TABLE 2 | Properties of the different regression models regarding intrinsic clearance for midazolam, tolbutamide, and chlorzoxazone, the amount of CYP450 proteins in
the liver for the biotransformation of the corresponding probe substrate and liver and body weight.
Y = 10a+b ∗ Xc+d
Y X a (SE) b (SE) c (SE) d (SE) R2
LW (g) BW (kg) 1.48 (0.014) 0.98 (0.015) 0.99
Female −0.04 (0.014) 0.06 (0.015)
Male 0.04 (0.014) −0.06 (0.015)
Intr Cl MDZ (nmol/min) LW (g) −0.87 (0.15) ns 1.50 (0.057) ns 0.92
Intr Cl TB (nmol/min) LW (g) −1.10 (0.15) ns 1.22 (0.055) ns 0.90
Intr Cl CZ (nmol/min) LW (g) 0.26 (0.084) 1.11 (0.032) 0.96
Female 0.04 (0.019) ns
Male −0.04 (0.019) ns
CYP450 proteins MDZ (pmol) LW (g) 1.66 (0.12) ns 1.36 (0.047) ns 0.94
CYP450 proteins TB (pmol) LW (g) 2.61 (0.19) ns 1.16 (0.07) ns 0.83
CYP450 proteins CZ (pmol) LW (g) 1.94 (0.12) ns 1.34 (0.047) ns 0.94
When the effect of gender was significant (P < 0.05) this was included in the equation. LW, liver weight (g); BW, body weight (kg); Intr Cl, intrinsic clearance; MDZ,
midazolam; TB, tolbutamide; CZ, chlorzoxazone; CYP450, cytochrome P450; ns, not significant; SE, standard error.
2010). This could be confirmed in our study where CYP3A46,
CYP3A, and CYP2C33v4 showed the highest correlation with
chlorzoxazone biotransformation when all pigs were considered.
However, the selectivity of involved CYP450 varied with age.
In 2-day-old piglets, CYP2C34 was the CYP450 of interest,
while at 8 weeks of age CYP2A19 seemed to be involved in the
biotransformation of chlorzoxazone. Finally, at 6–7 months,
CYP1A2, CYP2A19, CYP3A, CYP3A22, CYP2E1_1, CYP2E1_2,
and CYP4V2 showed a significant correlation. Wiercinska
and Squires (2010) found chlorzoxazone to be metabolized
by CYP1A1, CYP2E1, CYP2A19, and CYP2C33v4 which is in
line with the work presented here. However, it seems that age
has an influence on the specific CYP450 involved. The current
study also showed a significant correlation between CYP3A22,
CYP3A46, and CYP3A on the one hand, and chlorzoxazone on
the other hand. This is in contrast with Wiercinska and Squires
(2010) were no evidence of chlorzoxazone biotransformation
by CYP3A was found. The CYP3A involvement might be due
to the high correlation between CYP450 proteins mutually.
A high correlation coefficient doesn’t necessarily means that
the CYP450 of interest is also involved in the corresponding
biotransformation. Ideally, all selected CYP450 proteins should
be incubated individually with the substrates to evaluate their
contribution. Nevertheless, the use of chlorzoxazone as a porcine
CYP2E substrate is not advised. It should be noted that at 4 weeks
of age no significant correlations could be found for midazolam
or chlorzoxazone. CYP3A22 and CYP3A46 had the highest
coefficient of 0.47 and 0.35, respectively, with midazolam.
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FIGURE 4 | Illustration of the linear regression models. (A–C) Bilogarithmic plot of biotransformation rate for the full liver or intrinsic clearance in function of liver
weight. (D–F) Bilogarithmic plot of amount of CYP450 proteins in full liver involved in the biotransformation of the corresponding probe substrate in function of liver
weight. (G–I) Bilogarithmic plot of the ratio of the intrinsic clearance to their corresponding amount of CYP450 proteins in function of the liver weight. The graphs are
each time for midazolam, tolbutamide, and chlorzoxazone, respectively (left, middle, right).
Chlorzoxazone showed the best correlation with CYP2A19,
CYP4A, and CYP4A24 with a coefficient of 0.41, 0.46, and
0.46, respectively. Further research is required to evaluate the
age-related involvement of different CYP450 proteins in the
biotransformation of the corresponding substrates. Recently, in
our research group, Schelstraete et al. (2018) included two more
probe substrates to gain more insight in the selectivity of porcine
CYP450 enzymes (submitted).
There is ample evidence available that the increase in
biotransformation rate can be attributed to developmental
expression of CYP450 mRNA and proteins in humans and
pigs (Alcorn and McNamara, 2002; Van Peer et al., 2015)
The current study supports this hypothesis as an increase in
biotransformation rate with age can be related to an increase
in absolute amount of CYP450 proteins in the microsomes.
At 2 days of age only 14% of CYP450 proteins are present
compared to the 6- to 7-month-old pigs, which is reflected in
a very low biotransformation rate of the three substrates. Four-
and eight-week-old piglets have around 50% of CYP450 proteins
compared to the 6- to 7-month-old pigs. At 6–7 months of
age, the amount of CYP450 proteins is considered to be at
maximum adult values with 100% CYP450 proteins present in
the liver. Achour et al. (2011) was able to identify 10 CYP450
proteins in microsomes of two Suffolk white adult pigs. Both
CYP2D6 and CYP2A19 were most abundant, which is in line
with the results from the current study with an abundancy of
31 and 12% for males and 22 and 39% for females for CYP2D6
and CYP2A19, respectively. Achour et al. (2011) did not report
any sex differences, as the study was only done in two pigs.
Significant sex differences in activity and mRNA expression for
CYP1A, CYP1A2, and CYP2A were observed by Rasmussen et al.
(2011) in intact crossbreeds between Landrace × Yorkshire sire
and Duroc boars of 164 days old. The CYP2E1 activity was
higher in females compared to males, although not significant.
Despite the higher activity and mRNA expression in female pigs,
Rasmussen et al. (2011) did not found elevated levels of protein
with western blotting in females. This is in contrast with the
results presented here, where the 7 months old females have
significantly higher CYP1A2, CYP2A19, CYP3A22, CYP4V2,
CYP2E1_1, and CYP2E1_2 protein abundances. Higher female
protein concentrations were also observed by Skaanild and Friis
(1999) for CYP1A2 and CYP2E1 in both Göttingen minipigs
and Danish Landrace × Yorkshire × Duroc cross-breed pigs
(Skaanild and Friis, 1999). The 6-month-old males in the current
study showed significant higher CYP2C36 protein abundance
compared to females. The observed sex differences could be
attributed to sex hormones. Van den Broeke et al. (2015)
observed in 264 conventional pigs (Hybrid sow × Piétrain boar)
that at 5 months of age, all boars reached puberty, but only
8–31% of gilts were in puberty. Therefore, in this study, gilts
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of 7 months old were included to represent sows in puberty. In
order to evaluate whether these sex differences in CYP450 protein
abundance have an influence on the biotransformation of drugs,
selective substrates should be chosen to perform the same activity
measurements as described above for midazolam, tolbutamide,
and chlorzoxazone. In the current study, no significant sex
differences in enzyme activity were found for these substrates.
Although, this could have been expected for tolbutamide as
CYP2C36 is involved in its biotransformation. This could
possibly mean that other CYP450 enzymes contributed more to
the biotransformation of tolbutamide than CYP2C36.
In humans, several studies have been performed to determine
the protein abundance of the CYP450 enzymes in adult
microsomes. This resulted in great variations of reported values.
For example, Gröer et al. (2014) reported CYP3A4 abundance
of 32.6 pmol/mg microsomal protein while Achour et al.
(2017) measured 80.9 pmol/mg microsomal protein. A possible
explanation could be the different methods used, rendering
it difficult to compare the absolute porcine abundances with
human. A better way to make a correlation between these
two species is to compare the relative abundances. CYP2D6
(26%) and CYP2A19 (29%) are the most abundant CYP450
proteins in 6- to 7-month-old pigs, followed by CYP2E (13%)
and CYP2C (18%) proteins. In humans, however, CYP2C9
(20%) is found to be the most prominent CYP450 protein in
microsomes, followed by CYP3A4 (16%), CYP2E1 (13%), and
CYP2A6 (12%) (Kawakami et al., 2011). Unfortunately, data
regarding the ontogeny of the human CYP450 proteome is
limited. One study reported increasing levels of CYP2B6 with
age measured using immunoquantification (Pearce et al., 2016).
Sadler et al. (2016) performed a more thorough comparison
of CYP450 protein expression and activity profiles through
human development using activity-based protein profiling. The
porcine homologs of the human CYP450 enzymes marked by
a postnatal increase, namely members of the CYP1A, 2A, 3A,
2C, 2D, and 2E subfamilies, also increased in protein amount
in the current study. Sadler et al. (2016) however, did not
found a direct correlation between CYP450 activity and protein
expression. This is in contrast with the results presented here
where high correlation coefficients were found between the
biotransformation rate and certain CYP450 proteins. Further
research is required to evaluate whether pediatric microsomes
show a similar trend as seen in piglets, namely an increase in
amount of CYP450 proteins which can be correlated with an
increase in activity.
The biotransformation rate, as well as the amount of involved
CYP450 proteins showed a log-linear relationship with the log
of the liver weight (R2 ≥ 0.83) (Figure 4). In addition, the
log-ratio of the biotransformation rate to their corresponding
CYP450 proteins showed no linear correlation in function of the
log liver weight. This indicates that when the CYP450 protein is
present, it will contribute to the biotransformation of the probe
substrates regardless of the age or liver weight of the animal. The
developmental biotransformation rates observed in the present
study might thus be solely due to an increase in absolute amount
of CYP450 proteins. Further research is, however, required to
unravel the mechanisms regulating CYP450 enzyme ontogeny.
CONCLUSION
The ontogeny of porcine CYP450 enzymes was established on
three levels, i.e., enzyme activity with and without hepatic scaling
factor and protein abundance. The increase in biotransformation
rate with age could be attributed to an increase in absolute
amount of CYP450 proteins. Midazolam and tolbutamide
were shown to be selective probe substrates to evaluate both
human and porcine CYP3A and CYP2C enzyme activities,
respectively. Chlorzoxazone is not advised to use as a selective
porcine CYP2E substrate. This study provides more insight
in the ontogeny of CYP450 mediated phase I metabolism
in pigs, which can be used to support pediatric preclinical
research. Further research is required to evaluate age-related
changes in CYP450 biotransformation involvement and the
regulating developmental mechanisms. Also, other relevant
CYP450 enzymes and substrates should be evaluated.
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